No price
PreclinicalSmall molecule
No price is one of 8 small molecule programs targeting Cholecystitis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Cholecystitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Zofran
NovartisApproved
IC-Green
PProvepharm SAS
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Chirocaine
PPurdue Pharma LP
Preclinical
No price
HHadassah Medical Organization
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for No price. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHadassah Medical Organization